Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Rx Guaifenesin Ban Justified By Compliance Policy Guide – Adams Labs

This article was originally published in The Tan Sheet

Executive Summary

FDA should notify federal agencies that Rx single-ingredient, extended-release guaifenesin drugs are no longer available for contract purchase, Mucinex marketer Adams Labs says in Nov. 22 comments

You may also be interested in...

FDA Guaifenesin Crackdown Based On Adams Labs NDA “Improper” – Petition

FDA's call for the immediate removal of unapproved guaifenesin extended-release drugs from the market "improperly cedes FDA's enforcement discretion to private parties," four law firms maintain in a Nov. 12 citizen petition

Adams Mucinex Approval Spurs FDA Crackdown On Guaifenesin Products

Unapproved, single-ingredient guaifenesin extended-release Rx products should no longer be marketed because there is now an approved OTC version, according to FDA

Adams Labs Mucinex Marketing Strategy Targeting Healthcare Professionals

Adams Laboratories plans to launch Mucinex "long-acting" guaifenesin tablets with a behind-the-counter sales strategy

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts